Recent deals include the completed acquisition of efimosfermin, a potential treatment for liver disease, and new partnerships with Hengrui Pharma, aimed at developing up to 12 medicines in ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Driven by exceptional growth in Specialty Medicines and Vaccines, GSK’s second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding ...

Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...